All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
This product is the plasmid containing an encoded anti-EIF5 DMAb sequence. The plasmid can drive transcription and in vivo translation of the desired antibody.
Sub CAT. | DMAb Clone | DMAb Host | Target Species | DMAb Isotype | DMAb Immunogen | |
DMAb-0200-FY | 2E6-4C12 | Mouse | Human | IgG1, κ | EIF5 full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. Immunogen sequence: MSVNVNRSVS DQFYRYKMPR LIAKVEGKGN GIKTVIVNMV DVAKALNRPP TYPTKYFGCE LGAQTQFDVK NDRYIVNGSH EANKLQDMLD GFIKKFVLCP ECENPETDLH VNPKKQTIGN SCKACGYRGM LDTHHKLCTF ILKNPPENSD SGTGKKEKEK KNRKGKDKEN GSVSSSETPP PPPPPNEINP PPHTMEEEED DDWGEDTTEE AQRRRMDEIS DHAKVLTLSD DLERTIEERV NILFDFVKKK KEEGVIDSSD KEIVAEAERL DVKAMGPLVL TEVLFNEKIR EQIKKYRRHF LRFCHNNKKA KRYLLHGLEC VVAMHQAQLI SKIPHILKEM YDADLLEEEV IISWSEKASK KYVSKELAKE IRVKAEPFIK WLKEAEEESS GGEEEDEDEN IEVVYSKAAS VPKVETVKSD NKDDDIDIDA I | |
DMAb-0201-FY | 6D6G6 | Mouse | IgG2a | |||
DMAb-0202-FY | EPR12140B | Rabbit | IgG |
There are currently no customer reviews or questions for Anti-EIF5 DNA-encoded mAb (DMAb), pVAX1 (DMAb-0200-FY). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION